 | • レポートコード：MRC23Q36073 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥420,500 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥841,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のヒトiPSC市場について調査・分析し、世界のヒトiPSC市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（皮膚、血球）、用途別セグメント分析（学術研究、創薬及び新薬発見、毒性スクリーニング、再生医療、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Fujifilm Holding Corporation (CDI)、Ncardia、Sumitomo Dainippon Pharma、Astellas Pharma Inc、Fate Therapeutics, Inc、Pluricell Biotech、Cell Inspire Biotechnology、ReproCELLなどが含まれています。世界のヒトiPSC市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ヒトiPSC市場規模を推定する際に考慮しました。本レポートは、ヒトiPSCの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ヒトiPSCに関するビジネス上の意思決定に役立てることを目的としています。 ・ヒトiPSC市場の概要 - ヒトiPSCのタイプ別セグメント - 世界のヒトiPSC市場規模：タイプ別分析（皮膚、血球） - ヒトiPSCの用途別セグメント - 世界のヒトiPSC市場規模：用途別分析（学術研究、創薬及び新薬発見、毒性スクリーニング、再生医療、その他） - 世界のヒトiPSC市場規模予測（2018年-2029年） ・ヒトiPSC市場の成長トレンド - ヒトiPSCの地域別市場規模（2018年-2029年） - ヒトiPSC市場ダイナミクス - ヒトiPSCの業界動向 - ヒトiPSC市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：皮膚、血球 - 世界のヒトiPSCのタイプ別市場規模（2018年-2023年） - 世界のヒトiPSCのタイプ別市場規模（2024年-2029年） ・用途別セグメント：学術研究、創薬及び新薬発見、毒性スクリーニング、再生医療、その他 - 世界のヒトiPSCの用途別市場規模（2018年-2023年） - 世界のヒトiPSCの用途別市場規模（2024年-2029年） ・ヒトiPSCの地域別市場規模 - 北米のヒトiPSC市場規模（2018年-2029年） - アメリカのヒトiPSC市場規模（2018年-2029年） - ヨーロッパのヒトiPSC市場規模（2018年-2029年） - アジア太平洋のヒトiPSC市場規模（2018年-2029年） - 中国のヒトiPSC市場規模（2018年-2029年） - 日本のヒトiPSC市場規模（2018年-2029年） - 韓国のヒトiPSC市場規模（2018年-2029年） - インドのヒトiPSC市場規模（2018年-2029年） - オーストラリアのヒトiPSC市場規模（2018年-2029年） - 中南米のヒトiPSC市場規模（2018年-2029年） - 中東・アフリカのヒトiPSC市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Fujifilm Holding Corporation (CDI)、Ncardia、Sumitomo Dainippon Pharma、Astellas Pharma Inc、Fate Therapeutics, Inc、Pluricell Biotech、Cell Inspire Biotechnology、ReproCELL ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Human iPSCs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Human iPSCs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Human iPSCs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Human iPSCs in Academic Research is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Human iPSCs include Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology and ReproCELL, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human iPSCs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human iPSCs.
The Human iPSCs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Human iPSCs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human iPSCs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Segment by Type
Skin
Blood Cells
Segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human iPSCs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human iPSCs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Skin
1.2.3 Blood Cells
1.3 Market by Application
1.3.1 Global Human iPSCs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Academic Research
1.3.3 Drug Development and Discovery
1.3.4 Toxicity Screening
1.3.5 Regenerative Medicine
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human iPSCs Market Perspective (2018-2029)
2.2 Human iPSCs Growth Trends by Region
2.2.1 Global Human iPSCs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Human iPSCs Historic Market Size by Region (2018-2023)
2.2.3 Human iPSCs Forecasted Market Size by Region (2024-2029)
2.3 Human iPSCs Market Dynamics
2.3.1 Human iPSCs Industry Trends
2.3.2 Human iPSCs Market Drivers
2.3.3 Human iPSCs Market Challenges
2.3.4 Human iPSCs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human iPSCs Players by Revenue
3.1.1 Global Top Human iPSCs Players by Revenue (2018-2023)
3.1.2 Global Human iPSCs Revenue Market Share by Players (2018-2023)
3.2 Global Human iPSCs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human iPSCs Revenue
3.4 Global Human iPSCs Market Concentration Ratio
3.4.1 Global Human iPSCs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human iPSCs Revenue in 2022
3.5 Human iPSCs Key Players Head office and Area Served
3.6 Key Players Human iPSCs Product Solution and Service
3.7 Date of Enter into Human iPSCs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human iPSCs Breakdown Data by Type
4.1 Global Human iPSCs Historic Market Size by Type (2018-2023)
4.2 Global Human iPSCs Forecasted Market Size by Type (2024-2029)
5 Human iPSCs Breakdown Data by Application
5.1 Global Human iPSCs Historic Market Size by Application (2018-2023)
5.2 Global Human iPSCs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Human iPSCs Market Size (2018-2029)
6.2 North America Human iPSCs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Human iPSCs Market Size by Country (2018-2023)
6.4 North America Human iPSCs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human iPSCs Market Size (2018-2029)
7.2 Europe Human iPSCs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Human iPSCs Market Size by Country (2018-2023)
7.4 Europe Human iPSCs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human iPSCs Market Size (2018-2029)
8.2 Asia-Pacific Human iPSCs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Human iPSCs Market Size by Region (2018-2023)
8.4 Asia-Pacific Human iPSCs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human iPSCs Market Size (2018-2029)
9.2 Latin America Human iPSCs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Human iPSCs Market Size by Country (2018-2023)
9.4 Latin America Human iPSCs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human iPSCs Market Size (2018-2029)
10.2 Middle East & Africa Human iPSCs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Human iPSCs Market Size by Country (2018-2023)
10.4 Middle East & Africa Human iPSCs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Fujifilm Holding Corporation (CDI)
11.1.1 Fujifilm Holding Corporation (CDI) Company Detail
11.1.2 Fujifilm Holding Corporation (CDI) Business Overview
11.1.3 Fujifilm Holding Corporation (CDI) Human iPSCs Introduction
11.1.4 Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2018-2023)
11.1.5 Fujifilm Holding Corporation (CDI) Recent Development
11.2 Ncardia
11.2.1 Ncardia Company Detail
11.2.2 Ncardia Business Overview
11.2.3 Ncardia Human iPSCs Introduction
11.2.4 Ncardia Revenue in Human iPSCs Business (2018-2023)
11.2.5 Ncardia Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Detail
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Human iPSCs Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2018-2023)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Detail
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Human iPSCs Introduction
11.4.4 Astellas Pharma Inc Revenue in Human iPSCs Business (2018-2023)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Fate Therapeutics, Inc
11.5.1 Fate Therapeutics, Inc Company Detail
11.5.2 Fate Therapeutics, Inc Business Overview
11.5.3 Fate Therapeutics, Inc Human iPSCs Introduction
11.5.4 Fate Therapeutics, Inc Revenue in Human iPSCs Business (2018-2023)
11.5.5 Fate Therapeutics, Inc Recent Development
11.6 Pluricell Biotech
11.6.1 Pluricell Biotech Company Detail
11.6.2 Pluricell Biotech Business Overview
11.6.3 Pluricell Biotech Human iPSCs Introduction
11.6.4 Pluricell Biotech Revenue in Human iPSCs Business (2018-2023)
11.6.5 Pluricell Biotech Recent Development
11.7 Cell Inspire Biotechnology
11.7.1 Cell Inspire Biotechnology Company Detail
11.7.2 Cell Inspire Biotechnology Business Overview
11.7.3 Cell Inspire Biotechnology Human iPSCs Introduction
11.7.4 Cell Inspire Biotechnology Revenue in Human iPSCs Business (2018-2023)
11.7.5 Cell Inspire Biotechnology Recent Development
11.8 ReproCELL
11.8.1 ReproCELL Company Detail
11.8.2 ReproCELL Business Overview
11.8.3 ReproCELL Human iPSCs Introduction
11.8.4 ReproCELL Revenue in Human iPSCs Business (2018-2023)
11.8.5 ReproCELL Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details